Well, besides becoming an icon in the medical marijuana movement and running for the LP presidential nomination in 2008, he is taking libertarians, and the liberty movement, out of the trenches.

He is taking our message from the front lines of Main Street to the bottom line of Wall Street.

His new company, Cannabis Science Inc.  

(NASD OTCBB: CBIS), brings an opportunity to the libertarian community which has rarely, if ever, been offered before.

Make no mistake, Steve Kubby is no fool. He knows that starting a new company is a risky venture, but when you live day-to-day with life-threatening adrenal cancer and the authorities breathing down your neck because the medicine you use is not sanctioned by the government, just getting up in the morning is less than certain. When asked recently about the risk of starting a new company in tough economic times Kubby, who has had success in other entrepreneurial endeavors, said:

cannabinoid pharmaceutical company, is too risky and our stock too volatile. Yes, our venture is a risk and investors could lose everything, but where is there a ‘safe’ investment these days?”

According to the company’s website, “Recent advances in science have opened the door to develop, produce, and commercialize, a variety of effective whole plant cannabinoid based pharmaceutical products with a wide variety of important applications.”

Cannabis-derived pharmaceuticals have been hailed as “the next blockbuster” drug. Both scientific research and human experience indicate that mimicking the body’s own cannabis-like substances could play a major role in fighting a large number of diseases including multiple sclerosis, traumatic brain injury, fibromyalgia, arthritis, neuropathic pain, inflammatory bowel disease, depression, epilepsy, migraine, asthma, chronic pain, Alzheimer’s disease, atherosclerosis, and osteoporosis. These possibilities are in addition to traditional uses of cannabis-based medicines for glaucoma, chemotherapy-induced nausea, and correction of weight loss experienced by cancer and AIDS patients.

Mr. Kubby and his team of scientists are developing more effective ways to produce and commercialize the production of whole plant cannabinoid-based pharmaceutical products. Even today, new uses for cannabis are being found, such as the recent discovery that topical cannabis preparations can be effective against MIRSA (MethIcillin Resistant Staphylococcus Aureus), the deadly antibiotic-resistant flesh-eating disease. Other topical applications, which are largely non-psychoactive, would target localized pain, such as arthritis, and burns, but also neuropathic pain, for which there are few effective treatments.

Would the FDA consider approving cannabis-based drugs? The good news is that they already have. Synthetic THC, marketed as Marinol®, is already approved for chemotherapy-induced nausea and AIDs wasting syndrome. Cannabis Science will develop whole plant extracts, rather than single synthetic components of cannabis, that won’t necessitate smoking.

Clearly, the FDA favors that approach. Three years ago, the FDA gave the British company, GW Pharmaceuticals, permission to put their cannabis extract into human trials in the U.S. for cancer pain. The door for FDA-approved cannabis products has been opened and Steve Kubby intends for Cannabis Science to be in the forefront of this emerging niche. In an article published earlier today Steve encouraged others to join him in this exciting venture that has the potential of saving countless lives. He explains, “Acquiring a publicly-traded company, and selling our stock today, is a significant accomplishment, not just for us, but for all who believe in this important cause.

However, our effort is much more than that. We are a group of veteran activists, who are taking our cherished principles and ideals from Main Street to Wall Street. We are betting our lives and our fortunes on economic and social principles that will allow us to demonstrate to the business world that free markets and medical freedom are the wave of the future.”

So, why should we care about Cannabis Science Inc? Is it worth the risk? Kubby and his team of proven professionals certainly think so. According to a 2001 article published in the Canadian Medical Association Journal the market is certainly there. It revealed that, based on self-identified needs, an estimated 2% (or 400,000) Canadian adults were already using cannabis for medical purposes. That number would extrapolate into roughly 4 million in the US, where medical marijuana, legally accessible by about 25% of the population, is already estimated to be a $1 billion industry. Consequently, it would not be unreasonable to think that the global medical cannabis market will potentially reach several billion dollars.

Steve Kubby is confident and optimistic. When I asked him about the potential success of his new company he replied, “Will we succeed? Yes, but only if people such as yourself become involved, support our efforts and become personally invested in our future together.

Together, we CAN create the kind of world we dream about.”

Written by R. Lee Wright

R. Lee Wrights is a writer and political activist living in North Carolina. He is the co-founder and editor of the free speech online magazine 'Liberty For All' [http://www.libertyforall.net/?page_id=2].

He also serves as Director of Communications for Cannabis Science Inc .

Contact Lee at \n This e-mail address is being protected from spam bots, you need JavaScript enabled to view it This e-mail address is being protected from spambots. You need JavaScript enabled to view it .